Search

Your search keyword '"Herrera-Camacho, Irma"' showing total 8 results
Start Over Author "Herrera-Camacho, Irma" Journal expert opinion on therapeutic patents
8 results on '"Herrera-Camacho, Irma"'

1. OX40 agonists for cancer treatment: a patent review

Author

Cebada, Jorge, primary, Perez-Santos, Martin, additional, Bandala, Cindy, additional, Lara-Padilla, Eleazar, additional, Herrera-Camacho, Irma, additional, Rosas-Murrieta, Nora Hilda, additional, Millán-Pérez Peña, Lourdes, additional, Monjaraz, Eduardo, additional, Flores, Amira, additional, and Anaya-Ruiz, Maricruz, additional

Published
2020
Full Text
View/download PDF

8. OX40 agonists for cancer treatment: a patent review

Author

Cebada, Jorge, Perez-Santos, Martin, Bandala, Cindy, Lara-Padilla, Eleazar, Herrera-Camacho, Irma, Rosas-Murrieta, Nora Hilda, Millán-Pérez Peña, Lourdes, Monjaraz, Eduardo, Flores, Amira, and Anaya-Ruiz, Maricruz

Abstract

ABSTRACTIntroductionOX40 is an immune checkpoint in cancer and its presence in cancer is a good prognosis, making it a highly relevant target for the development of new immunotherapies.Areas coveredThe patent literature reveals vital information on new trends in cancer therapies. The authors used the patent databases of the six major patent offices in the world: United States Patent and Trademark Office, European Patent Office, World Intellectual Property Organization, Japan Patent Office, State Office of Intellectual Property of China and Korean Intellectual Property Office, to generate a panorama of patents related to OX40 agonists. Specific patents have been grouped into innovative patents and adoption patents.Expert opinionAn increasing trend in the development of OX40 agonists in cancer, particularly in the years 2018 and 2019. United States was the leader in generating patents, followed by China and England. Major pharmaceutical companies have at least one anti-OX40 agonist, MEDI6469 and MEDI-0562 (AstraZeneca), PF-04518600 (Pfizer), GSK3174998 (GlaxoSmithKline), BMS-986,178 (Bristol-Myers Squibb) and MOXR0916 (Roche), which represent 68% of clinical trials conducted with OX40 agonists.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results